Gene Therapies Becoming A Standard Capable Of Treating All Diseases Is Expected Only With Low Probability.

Will Gene Therapy Become A Standard Treatment For All Diseases By 2035?

Gene therapy is a one-time treatment that aims to correct missing or faulty genes, offering a revolutionary approach to hereditary diseases. In 2025, the U.S. Food and Drug Administration (FDA) approved Waskyra (etuvetidigene autotemcel) for Wiskott-Aldrich syndrome and a therapy for severe leukocyte adhesion deficiency, showing the platform is maturing. However, the idea that gene therapy will treat all diseases by 2035 is considered low probability, with an estimated likelihood of 8%.

What Is The Current Evidence For Gene Therapy Expansion?

Recent approvals target rare, single-gene disorders. For example, the FDA's approval of Waskyra in 2025 (source: FDA news release, February 2025) demonstrates clinical reality for rare diseases. This success is expected to expand to more rare conditions, then to common inherited diseases like hemophilia and sickle cell anemia by 2035. But expansion to complex diseases such as cancer and heart disease remains a long-term, uncertain goal.

What Are The Main Barriers To Universal Gene Therapy?

Three major obstacles persist: high cost (often over $1 million per treatment), vector safety risks (e.g., insertional mutagenesis), and manufacturing capacity limits. These factors make broad application to all diseases unlikely by 2035. Experts, including those at the National Institutes of Health (NIH), emphasize cautious expectations.

How Many Gene Therapy Approvals Are Expected By 2035?

The verification criterion for this prediction is a marked increase in approvals and expansion to new indications. As of 2025, there are over 20 approved gene therapies globally (source: Alliance for Regenerative Medicine). By 2035, analysts project 40 to 60 approvals, but this is far from covering all diseases. The FDA's guidance documents (2024) highlight that each new target requires extensive safety and efficacy data.

Why Is Treating All Diseases Unrealistic By 2035?

Complex diseases involve multiple genetic and environmental factors. Gene therapy currently excels at replacing a single missing gene, not modifying polygenic traits. For example, cancer immunotherapy uses gene-modified cells, but it is not a cure for all cancers. The American Society of Gene and Cell Therapy (ASGCT) notes that non-hereditary diseases require different delivery systems and long-term monitoring.

Frequently Asked Questions

Q1: What Is The Current Status Of Gene Therapy Approvals In 2025?

In 2025, the FDA approved Waskyra for Wiskott-Aldrich syndrome and a treatment for severe leukocyte adhesion deficiency. These approvals, listed in the FDA's database, show gene therapy is moving from research to clinical practice for rare diseases.

Q2: Which Diseases Are Most Likely To Be Treated By Gene Therapy By 2035?

Rare monogenic disorders will see the most growth, followed by common inherited conditions like hemophilia and sickle cell disease. For example, clinical trials for hemophilia B have shown durable factor IX expression (source: New England Journal of Medicine, 2023). Cancers and heart disease are less likely due to complexity.

Q3: What Are The Biggest Challenges To Making Gene Therapy Universal?

Cost remains a barrier; a single treatment can exceed $2 million. Vector safety, especially for viral vectors, requires improved designs. Manufacturing scale-up is slow. These issues, discussed in the World Health Organization's (WHO) 2024 report on gene therapy, limit widespread use by 2035.

In summary, while gene therapy will expand significantly by 2035, it will not become a standard for all diseases. The 8% probability reflects realistic hurdles in science, regulation, and economics.